ERBB2 and breast carcinoma: Therefore, we interrogated whether loss of Vangl2 impacts cell motility of diverse breast cancer cells of distinct molecular subtypes: triple-negative BT549, MDA-MB-231 and MDA-MB-468, HER2-positive SkBr3 and NDL, and ER/PR-positive MCF7 and T47D.